Literature DB >> 6112768

Behavioral and biochemical studies of the scopolamine-induced reversal of neuroleptic activity.

M G Ondrusek, C D Kilts, G D Frye, R B Mailman, R A Mueller, G R Breese.   

Abstract

Scopolamine reversed the reduction in avoidance responding caused by spiperone and antagonized the inhibitory effects of spiperone on the behavioral actions of d-amphetamine or apomorphine. Scopolamine-induced locomotor activity was greater in 6-hydroxydopamine (6-OHDA)-treated animals than in controls. This increase was prevented by administration of alpha-methyltyrosine, but not by inhibition of dopamine-beta-hydroxylase, indicating that this action of scopolamine was associated with presynaptic dopaminergic fibers. Therefore, the possibility that pre-synaptic dopaminergic function was the locus of the antagonism of spiperone by scopolamine was examined using drug interaction studies in 6-OHDA-treated rats. However, when 6-OHDA-treated rats were given alpha-methyltyrosine, scopolamine still reversed the spiperone blockade of apomorphine-induced locomotion. Although these data provided evidence for a post-synaptic action for this cholinergic blocking agent, scopolamine affected neither dopamine-stimulated adenylate cyclase activity nor 3H-spiperone binding in vitro. Furthermore, scopolamine did not alter the level of specific 3H-spiperone binding found in brain after in vivo administration. This suggests that the post-synaptic mechanism affected by scopolamine is different from the site affected by spiperone. Thus, it is concluded that scopolamine can affect both pre- or post-synaptic events associated with dopaminergic function and that both may contribute to the reversal of the actions of spiperone.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6112768     DOI: 10.1007/bf00431093

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Spiperone: a ligand of choice for neuroleptic receptors. 2. Regional distribution and in vivo displacement of neuroleptic drugs.

Authors:  P M Laduron; P F Janssen; J E Leysen
Journal:  Biochem Pharmacol       Date:  1978-02-01       Impact factor: 5.858

2.  A radioisotopic method for measuring the formation of adenosine 3',5'-cyclic monophosphate in incubated slices of brain.

Authors:  H Shimizu; J W Daly; C R Creveling
Journal:  J Neurochem       Date:  1969-12       Impact factor: 5.372

3.  Influences of cholinergic mechanisms on the function and turnover of brain dopamine.

Authors:  N E Andén; P Bédard
Journal:  J Pharm Pharmacol       Date:  1971-06       Impact factor: 3.765

4.  Dopamine and norepinephrine uptake by rat brain synaptosomes: relative inhibitory potencies of 1- and d-amphetamine and amantadine.

Authors:  J E Thornburg; K E Moore
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1973-01

5.  Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action.

Authors:  J T Coyle; S H Snyder
Journal:  Science       Date:  1969-11-14       Impact factor: 47.728

6.  Hyperactivity induced by injection of dopamine into the accumbens nucleus: actions and interactions of neuroleptic, cholinomimetic and cholinolytic agents.

Authors:  B Costall; S C Hui; R J Naylor
Journal:  Neuropharmacology       Date:  1979 Aug-Sep       Impact factor: 5.250

7.  Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats.

Authors:  T Schallert; I Q Whishaw; V D Ramirez; P Teitelbaum
Journal:  Science       Date:  1978-03-31       Impact factor: 47.728

8.  Antagonism of the antiavoidance effects of various agents by anticholinergic drugs.

Authors:  H M Hanson; C A Stone; J J Witoslawski
Journal:  J Pharmacol Exp Ther       Date:  1970-05       Impact factor: 4.030

9.  Dopamine--acetylcholine "balance" in nucleus accumbens and corpus striatum and its effect on hypothalamic self-stimulation.

Authors:  D N Stephens; L J Herberg
Journal:  Eur J Pharmacol       Date:  1979-03-15       Impact factor: 4.432

10.  Evidence for presynaptic cholinergic receptors on dopaminergic terminals: degeneration studies with 6-hydroxydopamine.

Authors:  J De Belleroche; Y Lugmani; H F Bradford
Journal:  Neurosci Lett       Date:  1979-02       Impact factor: 3.046

View more
  2 in total

1.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

2.  Similar effects of ethanol and flumazenil on acquisition of a shuttle-box avoidance response during withdrawal from chronic ethanol treatment.

Authors:  H E Criswell; G R Breese
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.